24/7 Newsfeed

Put Reason 24/7 on Your Site


Follow Reason 24/7 on Twitter and via RSS

New Breast Cancer Drug Deemed Too Expensive for the UK's NHS

LONDON (Reuters) – Roche’s new breast cancer drug Perjeta is not worth using on Britain’s state health service given its high price and the lack of data showing how long it might extend life, the country’s healthcare cost watchdog said.

The National Institute for Health and Clinical Excellence (NICE) said on Tuesday it could not be sure of Perjeta’s benefits, adding that not even the manufacturer estimated it would be considered cost-effective for the National Health Service.

NICE’s draft recommendation against using Perjeta is now open for consultation before final guidance is issued.

Source: Reuters . Read full article. (link)

Editor's Note: We invite comments and request that they be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of Reason.com or Reason Foundation. We reserve the right to delete any comment for any reason at any time. Report abuses.